Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 25 peer-reviewed journal articles Updated
Medical Genetics

The Path to Accuracy: Biology, Genetics, and Diagnosis

At a Glance

Glycogen Storage Disease (GSD) is now primarily diagnosed using genetic panel testing rather than invasive liver biopsies. A simple blood or saliva test can identify the exact genetic mutation causing your specific type of GSD, ensuring a safe and accurate diagnosis.

The journey to an accurate diagnosis for Glycogen Storage Disease (GSD) has fundamentally changed in recent years. What was once a process reliant on invasive surgical procedures has been transformed by genetic technology. Understanding the biological “why” behind your symptoms and the modern “how” of testing is essential for ensuring you receive the correct care.

The Biology: A Missing Key

Your body uses specialized proteins called enzymes to act as keys that lock and unlock energy stores. In GSD, one of these “keys” is either missing or doesn’t work correctly due to a genetic mutation [1].

  • GSD Ia (Von Gierke): The enzyme glucose-6-phosphatase is missing. This enzyme is the final “gatekeeper” that allows the liver to release sugar into the blood. Without it, sugar stays trapped, leading to severe low blood sugar (hypoglycemia) and a very large liver [2][3].
  • GSD III (Cori/Forbes): The debranching enzyme is deficient. This enzyme is needed to break down the “branches” of the glycogen molecule. Because it can’t be fully dismantled, abnormal glycogen builds up in both the liver and the muscles [4][5].
  • GSD V (McArdle): The enzyme myophosphorylase is missing in the muscles. This means muscles cannot access their own energy stores during exercise, leading to pain and fatigue [6].

The Diagnostic Standard: Genetics Over Biopsy

For decades, a liver biopsy (removing a small piece of liver tissue) was the only way to diagnose GSD. Today, current guidelines recommend Genetic Panel Testing (also called Next-Generation Sequencing or NGS) as the primary tool for diagnosis [7][8].

  • Why Genetics?: A single blood or saliva sample can now screen dozens of genes simultaneously [9]. This is more accurate, less expensive, and far less invasive than surgery [10][11].
  • The Role of Biopsy: While still a powerful tool for looking at liver health (like scarring or tumors), a biopsy is now usually considered a “second-tier” option for diagnosis—used only if genetic testing is unclear [12][13].

Essential Lab Markers

Before genetic testing, doctors often look for “clues” in your blood work. Depending on the GSD type, specific markers may be elevated:

  • Glucose & Lactate: In hepatic GSDs (like Type I), blood sugar is often low while lactate is high [14].
  • Creatine Kinase (CK): This is a marker of muscle breakdown. It is frequently high in muscle-focused GSDs like Type III or Type V [15][16].
  • Triglycerides & Uric Acid: These metabolic byproducts often rise when the liver is struggling to process energy correctly [17][18].

Newborn Screening and Pompe Disease

Pompe Disease (GSD II) is unique because it is increasingly included in Newborn Screening (NBS) programs [19]. This is critical because the most severe form (infantile-onset) requires immediate treatment with enzyme replacement therapy to prevent heart failure [20][21]. If a screen comes back positive, doctors follow up with an enzyme activity test and genetic confirmation to distinguish between early and late-onset forms [22][23].

Checklist: Is Your Diagnosis Complete?

A diagnosis is only “complete” when you have a formal laboratory report that includes:

  1. The Gene Name: (e.g., G6PC1, SLC37A4, GAA, AGL, PYGM).
  2. The Variant Nomenclature: The specific “code” for your mutation (e.g., c.526C>T).
  3. Zygosity: Whether you have one mutation or two. Note: Most GSDs are inherited in an ‘autosomal recessive’ pattern, meaning a person must inherit two mutations (one from each parent) to have the disease. However, some types like GSD IX are ‘X-linked,’ meaning males only need one mutation to be affected. [24]
  4. Classification: Proof that the mutation is “Pathogenic” (disease-causing) according to official standards [25].

Common questions in this guide

How is Glycogen Storage Disease diagnosed?
Today, genetic testing via a blood or saliva sample is the primary way to diagnose GSD. While liver biopsies were once the standard, they are now usually only needed if genetic test results are unclear.
Do I need a liver biopsy to be diagnosed with GSD?
In most cases, no. Modern guidelines recommend genetic panel testing first because it is highly accurate, screens dozens of genes at once, and is far less invasive than a surgical liver biopsy.
What does my genetic test report for GSD need to show?
A complete genetic diagnosis should include the specific gene name, the exact variant code for your mutation, whether you have one or two mutations, and confirmation that the mutation is known to cause disease.
What blood tests are used to check for Glycogen Storage Disease?
Doctors often look at markers like glucose and lactate for liver-related GSDs, or creatine kinase (CK) for muscle-related GSDs. High triglycerides and uric acid can also indicate the liver is struggling to process energy.
How is Glycogen Storage Disease inherited?
In most forms of GSD, you must inherit two mutated genes (one from each parent) to have the disease. This is called an autosomal recessive pattern. A few types, like GSD IX, are X-linked, meaning males only need one mutation to be affected.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Which specific gene was tested, and what is the exact code for my/my child's mutation?
  2. 2.Since we have a genetic diagnosis, is a liver biopsy still necessary for our management?
  3. 3.Does the genetic report mention if the mutations are homozygous or compound heterozygous, and what does that mean for our family?
  4. 4.Was a deletion/duplication analysis performed, or just standard sequencing?
  5. 5.What specific biomarkers (like glucose, lactate, or CK) are we tracking to see if the treatment is working?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (25)
  1. 1

    Glycogen storage diseases: Twenty-seven new variants in a cohort of 125 patients.

    Sperb-Ludwig F, Pinheiro FC, Bettio Soares M, et al.

    Molecular genetics & genomic medicine 2019; (7(11)):e877 doi:10.1002/mgg3.877.

    PMID: 31508908
  2. 2

    Genome editing using Staphylococcus aureus Cas9 in a canine model of glycogen storage disease Ia.

    Arnson B, Kang HR, Brooks ED, et al.

    Molecular therapy. Methods & clinical development 2023; (29()):108-119 doi:10.1016/j.omtm.2023.03.001.

    PMID: 37021039
  3. 3

    Computed Tomography and Magnetic Resonance Imaging Features of Primary and Secondary Hepatic Glycogenosis.

    Chen ZY, Liu YP, Zheng GJ

    Annals of hepatology 2018; (17(6)):903-905 doi:10.5604/01.3001.0012.7189.

    PMID: 30600303
  4. 4

    A Novel Gene Therapy Approach for GSD III Using an AAV Vector Encoding a Bacterial Glycogen Debranching Enzyme.

    Lim JA, Choi SJ, Gao F, et al.

    Molecular therapy. Methods & clinical development 2020; (18()):240-249 doi:10.1016/j.omtm.2020.05.034.

    PMID: 32637453
  5. 5

    Liver transplantation in patients with type IIIa glycogen storage disease, cirrhosis and hepatocellular carcinoma.

    Iglesias Jorquera E, Tomás Pujante P, Ruiz García G, et al.

    Revista espanola de enfermedades digestivas 2019; (111(2)):168-169 doi:10.17235/reed.2018.5856/2018.

    PMID: 30318896
  6. 6

    Novel variant in the PYGM gene causing late-onset limb-girdle myopathy, ptosis, and camptocormia.

    Chéraud C, Froissart R, Lannes B, Echaniz-Laguna A

    Muscle & nerve 2018; (57(1)):157-160 doi:10.1002/mus.25588.

    PMID: 28120463
  7. 7

    Diagnosis of hepatic glycogen storage disease patients with overlapping clinical symptoms by massively parallel sequencing: a systematic review of literature.

    Beyzaei Z, Geramizadeh B, Karimzadeh S

    Orphanet journal of rare diseases 2020; (15(1)):286 doi:10.1186/s13023-020-01573-8.

    PMID: 33054851
  8. 8

    Molecular diagnosis of glycogen storage disease type I: a review.

    Beyzaei Z, Geramizadeh B

    EXCLI journal 2019; (18()):30-46.

    PMID: 30956637
  9. 9

    Application of Next-Generation Sequencing (NGS) Techniques for Selected Companion Animals.

    Domrazek K, Jurka P

    Animals : an open access journal from MDPI 2024; (14(11)) doi:10.3390/ani14111578.

    PMID: 38891625
  10. 10

    Genetics of Hearing Loss--Nonsyndromic.

    Chang KW

    Otolaryngologic clinics of North America 2015; (48(6)):1063-72.

    PMID: 26275501
  11. 11

    [Despite Challenges and Pitfalls: How Ophthalmology Benefits from the Use of Next-Generation Sequencing].

    Bolz HJ

    Klinische Monatsblatter fur Augenheilkunde 2018; (235(3)):258-263 doi:10.1055/s-0043-122076.

    PMID: 29390234
  12. 12

    Hepatic Glycogenoses Among Children-Clinical and Biochemical Characterization: Single-Center Study.

    Korula S, Danda S, Paul PG, et al.

    Journal of clinical and experimental hepatology 2020; (10(3)):222-227 doi:10.1016/j.jceh.2019.07.007.

    PMID: 32405178
  13. 13

    Evaluating and monitoring liver disease severity in glycogen storage disease type IX: Performance of novel and established clinical scores.

    Paschall A, Koch RL, Mavis AM, et al.

    Genetics in medicine open 2026; (4()):103455 doi:10.1016/j.gimo.2025.103455.

    PMID: 42182040
  14. 14

    Hepatic Glycogenosis In Children: Spectrum Of Presentation And Diagnostic Modalities.

    Bilal H, Cheema HA, Fayyaz Z, et al.

    Journal of Ayub Medical College, Abbottabad : JAMC 2019; (31(3)):368-371.

    PMID: 31535508
  15. 15

    A rare co-occurrence of phosphorylase kinase deficiency (GSD type IXd) and alpha-glycosidase deficiency (GSD Type II) in a 53-year-old man presenting with an atypical glycogen storage disease phenotype.

    Picillo E, Onore ME, Passamano L, et al.

    Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology 2024; (43(1)):21-26 doi:10.36185/2532-1900-411.

    PMID: 38586167
  16. 16

    Recurrence of Myopathy After Liver Transplantation for Patients With End-Stage GSD Type IIIa.

    Wang H, Qu W, Liu Y, et al.

    Transplantation proceedings 2025; (57(3)):475-480 doi:10.1016/j.transproceed.2025.02.005.

    PMID: 40037949
  17. 17

    Successful treatment of diabetes associated with glycogen storage disease type Ia.

    Yuan X, Ma W, Wu X, et al.

    Diabetic medicine : a journal of the British Diabetic Association 2021; (38(2)):e14373 doi:10.1111/dme.14373.

    PMID: 32740965
  18. 18

    Report of an Iranian child with chronic abdominal pain and constipation diagnosed as glycogen storage disease type IX: a case report.

    Zamanfar D, Hashemi-Soteh SM, Ghazaiean M, Keyhanian E

    Journal of medical case reports 2024; (18(1)):14 doi:10.1186/s13256-023-04295-0.

    PMID: 38212860
  19. 19

    A roadmap for a patient-centred approach to Pompe disease management.

    Schoser B, Domínguez-González C, Laforet P, et al.

    Journal of neurology 2026; (273(2)):145.

    PMID: 41689635
  20. 20

    Evaluation of Experienced Clinical Events in Pompe Disease Based on Real-life Data.

    Erdem Karapınar F, Yazıcı H, Yoldaş Çelik M, et al.

    Neuropediatrics 2026; (57(2)):121-130 doi:10.1055/a-2777-2932.

    PMID: 41453391
  21. 21

    Introduction to the Newborn Screening, Diagnosis, and Treatment for Pompe Disease Guidance Supplement.

    Kishnani PS, Hwu WL,

    Pediatrics 2017; (140(Suppl 1)):S1-S3 doi:10.1542/peds.2016-0280B.

    PMID: 29162672
  22. 22

    Clinical features and genetic analysis of 5 cases of infantile-type glycogen storage disease type II: Case reports.

    Feng Q, Zhang MQ, Ba CX, Zhang YQ

    Medicine 2024; (103(35)):e39534 doi:10.1097/MD.0000000000039534.

    PMID: 39213226
  23. 23

    Performance of the Four-Plex Tandem Mass Spectrometry Lysosomal Storage Disease Newborn Screening Test: The Necessity of Adding a 2nd Tier Test for Pompe Disease.

    Chiang SC, Chen PW, Hwu WL, et al.

    International journal of neonatal screening 2018; (4(4)):41 doi:10.3390/ijns4040041.

    PMID: 33072961
  24. 24

    Targeted exome sequencing identified a novel frameshift variant in the PGAM2 gene causing glycogen storage disease type X.

    Nayab A, Alam Q, Alzahrani OR, et al.

    European journal of medical genetics 2021; (64(9)):104283 doi:10.1016/j.ejmg.2021.104283.

    PMID: 34237446
  25. 25

    [Analysis of two cases of glycogen storage disease type III due to compound heterozygous variants of AGL gene].

    Zhang M, Wang C, Xie Z, et al.

    Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics 2021; (38(11)):1073-1076 doi:10.3760/cma.j.cn511374-20200803-00578.

    PMID: 34729746

This page explains the biology and genetic testing of Glycogen Storage Disease for educational purposes. Always consult your geneticist or metabolic specialist for your specific diagnosis, lab results, and care plan.

Get notified when new evidence is published on Glycogen storage disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.